Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Susceptibility-Guided vs Empirical Therapy for H. Pylori
NCT05549115Unknown
- Sponsor
- Liaocheng City People's Hospital
- Start
- Sep 2022
- Primary completion
- Feb 2024
- Modality
- Polymer-based Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Randomised, open-label trial of esomeprazole, amoxicillin, clarithromycin, levofloxacin, furazolidone and 1 more in Helicobacter pylori infection (3 arms), sponsored by Liaocheng City People's Hospital. Primary endpoint: First-line H. pylori eradication rate. Status: unknown.
02
Drugs
esomeprazoleamoxicillinclarithromycinlevofloxacinfurazolidone
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT05549115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549115.